Glucotrack Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled 'Methods And Systems For Continuously Monitoring The Glucose Level Of A Patient'

Glucotrack, Inc. ("Glucotrack", or the "Company") (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled "Methods and Systems for Continuously Monitoring the Glucose Level of a Patient." The allowed claims expand the intellectual property protecting the Company’s continuous blood glucose monitoring (CBGM) platform as it advances its multi-year, fully implantable CBGM system toward commercialization.

The filing adds to the three CBGM patents issued by the USPTO in late 2025 (US 12,453,494; US 12,458,257; and US 12,458,258), further protecting key technologies across the Company's sensor architecture.